Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.
![](https://i.ytimg.com/vi/iISbVbqOhY4/maxresdefault.jpg)